People with serious mental illness (SMI), including schizophrenia, bipolar disorder, and
major depressive disorder, have a higher mortality rate and shortened life expectancy. This …

Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …

Aim Initiating antipsychotic medication frequently induces rapid, clinically significant weight
gain. We aimed to evaluate the effectiveness of a lifestyle and life skills intervention …

Introduction: Second-generation antipsychotics (SGAs) are widely used in several
psychiatric disease entities and exert to a different extent a risk for antipsychotic-induced …

Metabolic side effects of antipsychotic drugs can have serious health consequences and
may increase mortality. Although persons with schizophrenia often take these drugs for a …

The outcome of first-episode psychosis (FEP) is highly variable, ranging from early
sustained recovery to antipsychotic treatment resistance from the onset of illness. For …

Background: Psychotropic drugs can induce substantial weight gain, particularly during the
first 6 months of treatment. The authors aimed to determine the potential predictive power of …

Objective Acquiring a diagnosis of schizophrenia reduces life expectancy for many reasons
including poverty, difficulties in communication, side‐effects of medication and access to …

Background Adjunctive metformin is the most well-studied intervention in the
pharmacological management of antipsychotic-induced weight gain (AIWG). Although a …